title: Immunogenicity of hepatitis A vaccine in children with celiac disease.
abstract: OBJECTIVE
  The response to hepatitis A vaccine has not been studied in children with celiac disease (CD). The aim of the present study was to evaluate the immunogenicity of an inactivated hepatitis A virus (HAV) vaccine and the effect of the human leukocyte antigen (HLA) type on immunogenicity in children with CD.
  
  
  METHODS
  Thirty-three patients with CD and 62 healthy controls were enrolled in the study. Inactivated HAV vaccine (Havrix; GlaxoSmithKline Biologicals, Rixensart, Belgium) containing 720 enzyme-linked immunosorbent assay units of alum-adsorbed hepatitis A antigen was administered intramuscularly in a 2-dose schedule at 0 and 6 months. Seroconversion rates and antibody titers of HAV were measured at 1 and 7 months.
  
  
  RESULTS
  At 1 month, seroconversion rates were 78.8% and 77.4% and geometric mean titers were 50.7 and 49.9 mIU/mL in the CD and control groups, respectively (P > 0.05). At 7 months, seroconversion rates were 97% and 98.4% and geometric mean titers were 138.5 and 133 mIU/mL in the CD and control groups, respectively (P > 0.05). The most frequent HLA types were HLA-DQ2, -DR3, and -DR7 alleles in patients with CD and HLA-DQ3, -DQ6, -DR11, and -DR14 in the controls. There was no association between HLA alleles and antibody titers of hepatitis A vaccine.
  
  
  CONCLUSIONS
  Children with CD have a good immune response to hepatitis A vaccine, similar to healthy controls.
authors.affiliation: Department of Pediatric Gastroenterology, Gazi University Faculty of Medicine, Ankara, Turkey. drsinansari@yahoo.com
authors.forename: Sinan
authors.initials: S
authors.lastname: Sari
authors.forename: Buket
authors.initials: B
authors.lastname: Dalgic
authors.forename: Bilkay
authors.initials: B
authors.lastname: Basturk
authors.forename: Sevim
authors.initials: S
authors.lastname: Gonen
authors.forename: Oguz
authors.initials: O
authors.lastname: Soylemezoglu
mesh_terms: D000483:Alleles; D016022:Case-Control Studies; D002446:Celiac Disease / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006680:HLA Antigens / Q000187:drug effects; D006506:Hepatitis A / Q000517:prevention & control*; D035922:Hepatitis A Antibodies / Q000097:blood*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000276:immunology*; D017957:Hepatitis A Virus, Human / Q000276:immunology; D006801:Humans; D008297:Male; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D006680:HLA Antigens; D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D015164:Vaccines, Inactivated